Member Info for Matml74

SEE rns’d it last year.

https://www.lse.co.uk/rns/SEE/bipartisan-infrastructure-legislation-grqebkj87i6gqht.html

Would suggest those numbers don’t include the the large numbers of contracted out engineers in Vietnam so not really reflective of size of each other workforce.

55m of them got sold at 5.555p

Seize, This has been said to you before. Magna have invested the money. Getting to 11p is irrelevant to SEE getting the money.

I’m going to bury my head in the sand and pretend the Magna deal doesn’t exist and then I am going to ignore $400m+ worth of high margin contracts and then I am really going to fret over the appointment of a CFO who has moved to SEE from a $4 billion dollar company and then I might make a share price prediction that SEE should be valued at leat £1. FFS where do these guys come from.

Anyway next week we are due a few TR1’s. Will be interesting to see who took those shares today and who was silly enough to offload them.

Phil, equally he may have been headhunted and has 6 months gardening leave before starting the new role.

He does seem a very good fit based on previous history in a growth tech stock and where SEE currently stands today.

Either way Naomi has done a great job and looks like we have a very well credentialed CFO for the large growth phase coming over the next few years.

Would be strange to do that when the rns states “ an upfront payment to Seeing Machines of US$10m, with an additional US$7.5m payable over the following 2 years”

Because they are dealing with a number of OEM's who's cars are in production and there is a lag on the OEM reporting auto dms production numbers to SEE. PM has stated it is around a month or so before they get production numbers.

Fleet is internal so they would have those numbers. Bdms contracts have been reported in the past but with all contracts they will only report significant material contracts not every little contract they win. With the stage the company is at now they should only be reporting contracts worth 10's of millions +.

I understand the statements in the rns but they can’t and won’t present the data to a room full of people without providing an rns first. The rns may come the same day as the science day presentation but the market will need to be given time to digest and be available to all, prior to any presentation like that.

The trial data will be rns’d before the science day. It’s market sensitive and needs to be provided to the market prior to any presentation like that.

Yes if you combine the ethical stance outlined in that piece with the fact that the trial is measuring PK data, secondary endpoints that focus on efficacy, a swathe of side effect and safety measures being reviewed each fortnight and multiple dose escalations significantly above standard dox dosage then all indicators point to a positive outcome of phase 1a.

Ignore trolls who suggest that dose escalation is only being done as no effect has been seen. It is not the reality of how the trial is run from a data collection standpoint or the ethics involved.

That don’t report year on year contract wins. They report yearly NRE which is a reflection of auto OEM wins and more importantly auto licence revenue, for which the company has currently received less than $US5m of the $400m+ that they have won. It’s the later which is about to rocket over the next few years.

Latic, that logic means that Tmac, LGchem, Affyexel, Point etc etc etc don’t exist.

Would also be pulling the wool over the eyes of the party who agreed the CLN. Unlikely that they raised money to have a £10-20m turnover diagnostics business as their fallback.

There will be plenty of things to subscribe to within the ****pit but one of them won’t be DMS as it will be a mandated safety feature required for all cars, starting in the EU and then followed by the rest of the world.

Their NCAP compliance relates to their driver assistance systems but I don’t believe these systems include any DMS so they won’t help OEM’s meet NCAP required for driver monitoring.

Lack of faith LOL. Go and take a look through the history of director share purchases/sales and see how many have been sold over the years. The chair bought at 11p. PM can buy 12 million at 4.4p with his options so why would he buy at 7?

Kate bought plenty at 4p so no need for her to average down. I am more concerned with them ensuring they deliver on the growth of the business, which they are doing in spades, than a token purchase of shares.

Seize, As I understand the CLN with Magna SEE have already drawn down $US30m first tranche of the $47.5m. Manna can choose to convert the principal and interest at any stage during the 4 year term into shares at 11p.

Our share price is irrelevant to the company getting hold of the cash.

There was a $17m dollar exclusive license rns a couple of weeks ago. :-) ……… but yes you can never have enough RNS’s!

Seems we have been working with BAE for a while. I remember something from earlier in the year.

What we were promised with this years FY results was some forward guidance. Cenkos’s guidance doesn’t go past 2023. Think it’s time for the company, it’s broker or Cenkos to give us a medium term picture for the company’s path to profitability.